I Teos Therapeutics, Inc. ITOS
Institutional shares held
4.28 Million
0
calls
0
puts
Total value of holdings
$43.5M
$0
calls
$0
puts
Market Cap
$361M
35,575,300
Shares Out.
Institutional ownership
12.03%
# of Institutions
14
We take great care to ensure that the data presented and summarized in this overview for iTeos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITOS
View all-
Black Rock Inc. New York, NY3.73MShares$37.9 Million0.0% of portfolio
-
Eagle Asset Management Inc St Petersburg, FL152KShares$1.54 Million0.01% of portfolio
-
Ea Series Trust Havertown, PA101KShares$1.03 Million0.05% of portfolio
-
Fny Investment Advisers, LLC65KShares$659,7500.27% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL60.4KShares$613,0700.0% of portfolio
-
Tekla Capital Management LLC45.7KShares$464,2100.02% of portfolio
-
Putnam Investments LLC Boston, MA34.9KShares$354,2750.0% of portfolio
-
Bluefin Capital Management, LLC New York, NY30.5KShares$309,8790.09% of portfolio
-
Credit Suisse Ag Zurich, V826.7KShares$270,6090.0% of portfolio
-
Nine Point Two Capital LLC Los Angeles, CA17.7KShares$179,4210.08% of portfolio
Latest Institutional Activity in ITOS
Top Purchases
Top Sells
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Insider Transactions at ITOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2025
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
46,300
-100.0%
|
-
|
|
Aug 29
2025
|
Matthew Gall Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
89,429
-100.0%
|
-
|
|
Aug 29
2025
|
David Feltquate Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,000
-100.0%
|
-
|
|
Aug 29
2025
|
Michel Detheux Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
94,027
-100.0%
|
-
|
|
Aug 29
2025
|
Michel Detheux Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
153,903
-100.0%
|
-
|
|
Aug 29
2025
|
Matthew Call Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
161,898
-100.0%
|
-
|
|
Jun 10
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
137,910
+50.0%
|
$551,640
$4.3 P/Share
|
|
Jun 10
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,400
+7.99%
|
$105,600
$4.3 P/Share
|
|
Jun 10
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
43,883
-100.0%
|
$438,830
$10.02 P/Share
|
|
Jun 10
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,400
-5.82%
|
$84,000
$10.02 P/Share
|
|
Jun 09
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
43,882
-100.0%
|
$438,820
$10.03 P/Share
|
|
Jun 09
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
43,882
+50.0%
|
$175,528
$4.3 P/Share
|
|
Jun 09
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,400
-5.82%
|
$84,000
$10.03 P/Share
|
|
Jun 09
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,400
+5.5%
|
$33,600
$4.3 P/Share
|
|
Jun 06
2025
|
David Hallal |
SELL
Open market or private sale
|
Direct |
38,228
-100.0%
|
$382,280
$10.24 P/Share
|
|
Jun 06
2025
|
David Hallal |
BUY
Exercise of conversion of derivative security
|
Direct |
38,228
+50.0%
|
$152,912
$4.3 P/Share
|
|
Jun 06
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
43,882
-100.0%
|
$438,820
$10.21 P/Share
|
|
Jun 06
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
43,882
+50.0%
|
$175,528
$4.3 P/Share
|
|
Jun 06
2025
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,400
-5.82%
|
$84,000
$10.21 P/Share
|
|
Jun 06
2025
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,400
+5.5%
|
$33,600
$4.3 P/Share
|
Last 12 Months Summary
Buy / Acquisition
5.66M
Shares
From
9
Insiders
| Open market or private purchase | 4.96M shares |
|---|---|
| Exercise of conversion of derivative security | 510K shares |
| Grant, award, or other acquisition | 187K shares |
Sell / Disposition
3.26M
Shares
From
10
Insiders
| Open market or private sale | 2.67M shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 593K shares |